Novavax (NVAX) missed Wall Street expectations Monday after its second quarter earnings showed softer-than-expected demand in global vaccine sales, forcing the company to slash its 2022 outlook by 50% to $2 billion.
While at least $400 million in revenue has come in since July 1, the company has not fulfilled orders for low- and middle-income countries (LMICs) through the global COVAX program and anticipates no further orders from the U.S. this year, according to company executives Monday.
But…
Source link